<DOC>
	<DOCNO>NCT00484120</DOCNO>
	<brief_summary>This study valuate safety efficacy treatment 3 % Diclofenac Nano-Emulsion Cream versus Placebo subject osteoarthritis knee .</brief_summary>
	<brief_title>Proof-of Concept Study Topical 3 % -Diclofenac-Nano-Emulsion Cream Knee OA Pain</brief_title>
	<detailed_description>This multi-center , double-blind , placebo-controlled , multiple-dose , parallel treatment study . A total 126 subject randomize receive either 3 % -Diclofenac-NE cream placebo cream respectively . Following screen washout period previous treatment subject enrol self-apply study medication . During study , subject apply 3 % -Diclofenac-NE placebo cream three time daily 28 day complete home-diary . Subjects visit clinic mid-treatment follow examination final examination end treatment .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Males females 50 year age . 2 . Patients primary osteoarthritis least single knee joint , grade 2 3 base Kellgren Lawrence classification system . 3 . Radiographic evidence consistent OA carry within 6 month screen . 4 . Pain present least half day previous month least 48h prior screen visit . 5 . Eligible subject must use oral , topical rectal NSAID within past 6 month screen . 6 . At baseline , 1 week withdrawal period analgesic/antiinflammatory medication , subject flare pain . 7 . Able read , comprehend , sign consent form . 8 . Examined authorized physician medically clear participate study . 9 . In general good health contraindication investigational medicinal product . 1 . Secondary osteoarthritis . 2 . Presence serious unstable medical condition ( e.g. , malignancy , severe neurological impairment uncontrolled hypertension ) poor general health interfere compliance assessment study physician 's discretion . 3 . OA cause significant pain joint knee . 4 . Any rheumatic nonrheumatic joint disease painful condition within past month ( e.g . fibromyalgia ) . 5 . Knee surgery knee trauma time previous year subject treatment plan within study period could alter degree nature pain ( e.g . arthroscopic technique , osteotomy , joint replacement surgery etc. ) . 6 . Active history gastrointestinal ulceration bleed within past 5 year . 7 . Presence significant active psychiatric disorder include major depression subject receive antipsychotic medication . 8 . Existence dermatological condition knee . 9 . Subjects disable congestive heart failure ( CHF ) , angina , pulmonary disease . 10 . Clinically significant abnormal blood result . 11 . Subjects arthrocentesis prior study . 12 . Concomitant treatment physical and/or occupational therapy . 13 . Prior use type NSAID analgesic take first dose investigational medicinal product . Rescue treatment allow study 14 . Change sedative CNS/psychotropic agent within past month . 15 . Chronic treatment anticoagulant ( e.g . Warfarin ) . 16 . Subjects treatment corticosteroid . 17 . Subjects use topical analgesic include OTC product . 18 . Females pregnant , lactating , childbearing potential , postmenopausal less 2 year use medically approve method contraception ( i.e. , oral , transdermal , implanted contraceptive , intrauterine device , diaphragm , condom , abstinence , surgical sterility ) , females test positive urinebased pregnancy test . 19 . Active alcoholism substance abuse . 20 . Has take investigational drug use investigational device within past 30 day . 21 . History hypersensitivity and/or idiosyncrasy diclofenac excipients employ study , aspirin NSAIDS . 22 . Has previously enter study . 23 . Any condition investigator 's judgement preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Diclofenac</keyword>
	<keyword>Nano-emulsion</keyword>
</DOC>